anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Blocking the RhoA/ROCK II/MLC 2 (Ras homolog gene family member A/Rho kinase II/myosin light chain 2) signaling pathway can initiate neuroprotective mechanisms against neurological diseases such as stroke, cerebral ischemia, and subarachnoid hemorrhage. Nevertheless, it is not clear whether and how disrupting the RhoA/ROCK II/MLC 2 signaling pathway changes the pathogenic processes of the blood-brain barrier (BBB) after intracerebral hemorrhage (ICH). The present investigation included the injection of rat caudal vein blood into the basal ganglia area to replicate the pathophysiological conditions caused by ICH.
METHODS: Scalp acupuncture (SA) therapy was performed on rats with ICH at the acupuncture point "Baihui"-penetrating "Qubin," and the ROCK selective inhibitor fasudil was used as a positive control to evaluate the inhibitory effect of acupuncture on the RhoA/ROCK II/MLC 2 signaling pathway. Post-assessments included neurological deficits, brain edema, Evans blue extravasation, Western blot, quantitative polymerase chain reaction, and transmission electron microscope imaging.
RESULTS: We found that ROCK II acts as a promoter of the RhoA/ROCK II/MLC 2 signaling pathway, and its expression increased at 6 h after ICH, peaked at 3 days, and then decreased at 7 days after ICH, but was still higher than the pre-intervention level. According to some experimental results, although 3 days is the peak, 7 days is the best time point for acupuncture treatment. Starting from 6 h after ICH, the neurovascular structure and endothelial cell morphology around the hematoma began to change. Based on the changes in the promoter ROCK II, a 7-day time point was selected as the breakthrough point for treating ICH model rats in the main experiment. The results of this experiment showed that both SA at "Baihui"-penetrating "Qubin" and treatment with fasudil could improve the expression of endothelial-related proteins by inhibiting the RhoA/ROCK II/MLC 2 signaling pathway and reduce neurological dysfunction, brain edema, and BBB permeability in rats.
CONCLUSION: This study found that these experimental data indicated that SA at "Baihui"-penetrating "Qubin" could preserve BBB integrity and neurological function recovery after ICH by inhibiting RhoA/ROCK II/MLC 2 signaling pathway activation and by regulating endothelial cell-related proteins.
The availability of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as liraglutide and semaglutide, and a GLP-1 and glucose dependent insulinotropic polypeptide coagonist (tirzepatide) represents a paradigm shift in the management of both type 2 diabetes and obesity. There is now considerable attention, including in the public media, on the effect of both long-acting and short-acting GLP-1RAs to delay gastric emptying. Although slowed gastric emptying is integral to reducing post-prandial blood glucose responses in type 2 diabetes, marked slowing of gastric emptying might also increase the propensity for longer intragastric retention of food, with a consequent increased risk of aspiration at the time of surgery or upper gastrointestinal endoscopy. This Personal View summarises current knowledge of the effects of GLP-1 and GLP-1RAs on gastrointestinal physiology, particularly gastric emptying, and discusses the implications for the development of sound pre-operative or pre-procedural guidelines. The development of pre-procedural guidelines is currently compromised by the poor evidence base, particularly in relation to the effect of long-acting GLP-1RAs on gastric emptying. We suggest pre-procedural management pathways for individuals on GLP-1RA-based therapy and discuss priorities for future research.
PURPOSE: To obtain a new compound having antipyretic, analgesic, anti- inflammatory actions, esp. the selectively inhibitory action for cycloxygenase-2, thus useful as an anti-inflammatory agent low in side effects such as digestive tract disorders. CONSTITUTION: This new compound (salt) is expressed by formula I (R and R1 are such that one group thereof is methylsul-fonylphenyl, aminosulfonylphenyl, etc., the other being a 5-7C cycloalkyl, thienyl, etc.; R2 is a lower alkyl), e.g. 4-cyclohexyl-2-methyl-5(4-methylsulfonyl-phenyl)oxazole. The compound of formula I is obtained, for example, by the following process: a compound of formula II (X is a halogen) is reacted with a compound of formula III in the presence of a metal such as Zn in an inert solvent such as toluene at room temperature and the resultant product is refluxed under heating in a lower carboxylic acid of the formula R2 COOH in the presence of a complex such as tetraacetato to obtain a compound of formula IV, which is, in turn, refluxed under heating in the presence of an ammonium salt such as ammonium acetate in an acidic solvent such as formic acid.
This is a Phase II, Randomized, Placebo-Controlled, Double-Blinded, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease. 100 patients will be enrolled. Eligible participants are at high or very high exposure risk of contracting COVID-19. The primary endpoint of this study is to provide immune support against COVID-19, measured by the percentage of subjects that develop symptoms of COVID-19. In addition, participants will be monitored for overall clinical status by standard clinical laboratories and inflammatory markers. Participants will complete Short Form Health Survey (SF-36) and depression module (PHQ-9) questionnaires.
<P>PROBLEM TO BE SOLVED: To provide a new compound having an antitumor activity and an inhibitory activity for cell motility and to provide a method for producing the same and an antitumor agent and a cell motility inhibitor comprising the same as an active ingredient and a new microorganism having the ability to produce the compound.  <P>SOLUTION: The compound is represented by general formula (I). The method for producing the compound comprises culturing the microorganism belonging to the genus Aspergillus and having the ability to produce the compound and collecting the compound from the resultant cultured product. The antitumor agent and the cell motility inhibitor comprising the compound as the active ingredient are provided. An Aspergillus sp. F7720 strain (FERM P-18198) having the ability to produce the compound is obtained.  <P>COPYRIGHT: (C)2004,JPO
Sepsis is a life-threatening condition that has the potential to multiple organ dysfunction and mortality. One of its frequent complications is disseminated intravascular coagulation (DIC), characterized by hyperactive clotting mechanisms that cause widespread clot formation and tissue damage. This study aimed to investigate early diagnostic markers of sepsis-associated DIC by comparing inflammatory factor levels, 28-day survival rates, coagulation function, and markers between patients with sepsis (non-DIC group) and those with sepsis-induced DIC (DIC group). The study analyzed the diagnostic efficacy of coagulation function and markers in predicting the occurrence and prognosis of sepsis-associated DIC, presenting survival curves. Results indicated significantly increased levels of APTT, TAT, tPAIC, PIC, and sTM in the DIC group compared to the non-DIC group. Sequential Organ Failure Assessment (SOFA) scores on days 1, 3, and 7 were notably lower in the non-DIC group. Correlation analysis revealed positive associations between PT, APTT, TAT, tPAIC, PIC, sTM levels, and SOFA scores, as well as negative associations with Fib and SOFA scores. Survival curves showed substantially lower mortality rates in the non-DIC group, highlighting significant survival disparities between groups. Combining all four coagulation indicators (TAT+ tPAIC + PIC + sTM) showed promising diagnostic value in evaluating disease severity, early DIC diagnosis, and sepsis prognosis.
The invention provides a combined medicine for preventing and treating tumors, which has the effects of reducing side effects of chemotherapy and radiotherapy. The combined medicine for preventing and treating tumors comprises cucurbitacine and at least one of coenzyme Q10 and taurine, wherein the weight ratio of cucurbitacine to coenzyme Q10 is 1:(0.1-10000); the weight ratio of cucurbitacine to taurine is 1:(0.1-10000). When the medicine is formed by cucurbitacine, coenzyme Q10 and taurine, the weight ratio of cucurbitacine to coenzyme Q10 to taurine is 1:(0.1-10000):(0.1-10000). The dosage is also provided. The combined medicine can be processed into tablets, capsules, granules, powder, patches, ointment, suspension, syrup, sustained-release preparations, nano-particles or emulsion and other preparations with pharmaceutically acceptable carriers commonly or respectively. The combined medicine can be used in chronic hepatitis treatment and prevention and treatment of cancers in clinical application.
The investigators are trying to determine a safe dose of KPT-330 and will be giving participants different dose levels of the study drug. Three to six participants will receive the starting dose of the drug. If the side effects are not too severe, the next group of participants will take the study drug at a higher dose level. Up to 3 dose levels of the study drug will be tested, but once each participant has been assigned a dose level, the participant will always receive the same dose. The highest dose that people can be given safely is called the maximum tolerated dose (MTD). Once the MTD is determined, up to 10 additional participants will receive that dose to further study the drug.

Participants between the age of ≥18 months (540 days) and ≤ 21 years with relapsed (second or subsequent relapse) or refractory ALL or AML will be eligible to enroll. KPT-330 will be administered twice a week on Days 1 and 3 for four weeks (a cycle is 4 weeks). All participants will receive intrathecal chemotherapy on Day 1 of each cycle. Participants with CNS-2 disease will receive additional doses of IT chemo. Pharmacokinetic (PK) samples will be collected during Cycle 1 on Days 1-3 and 15. PK samples will be collected during Cycle 2 on Day 15. Pharmacodynamic (PD) samples will be collected during Cycle 1 on Days 1-3. PD samples will be collected during Cycle 2 on Day 15. Additional optional correlative biology sample will be collected. Participants are monitored closely for adverse events. Participants will have physical exams and blood work more than once a week during all cycles.
BACKGROUND: Despite infection control guidance, sporadic nosocomial coronavirus disease 2019 (COVID-19) outbreaks occur. We describe a complex severe acute respiratory coronavirus virus 2 (SARS-CoV-2) cluster with interfacility spread during the SARS-CoV-2 δ (delta) pandemic surge in the Midwest.
SETTING: This study was conducted in (1) a hematology-oncology ward in a regional academic medical center and (2) a geographically distant acute rehabilitation hospital.
METHODS: We conducted contact tracing for each COVID-19 case to identify healthcare exposures within 14 days prior to diagnosis. Liberal testing was performed for asymptomatic carriage for patients and staff. Whole-genome sequencing was conducted for all available clinical isolates from patients and healthcare workers (HCWs) to identify transmission clusters.
RESULTS: In the immunosuppressed ward, 19 cases (4 patients, 15 HCWs) shared a genetically related SARS-CoV-2 isolate. Of these 4 patients, 3 died in the hospital or within 1 week of discharge. The suspected index case was a patient with new dyspnea, diagnosed during preprocedure screening. In the rehabilitation hospital, 20 cases (5 patients and 15 HCWs) positive for COVID-19, of whom 2 patients and 3 HCWs had an isolate genetically related to the above cluster. The suspected index case was a patient from the immune suppressed ward whose positive status was not detected at admission to the rehabilitation facility. Our response to this cluster included the following interventions in both settings: restricting visitors, restricting learners, restricting overflow admissions, enforcing strict compliance with escalated PPE, access to on-site free and frequent testing for staff, and testing all patients prior to hospital discharge and transfer to other facilities.
CONCLUSIONS: Stringent infection control measures can prevent nosocomial COVID-19 transmission in healthcare facilities with high-risk patients during pandemic surges. These interventions were successful in ending these outbreaks.
This registry will prospectively collect a core set of data on patients undergoing knee or hip replacement. This registry will include a variety of different products, implants, technologies and procedures. The registry will also collect any adverse events/complications that occur during or following these surgeries. This database can also be utilized in the future to answer research questions, by retrospectively going back through the data. This information also may go to insurance companies or hospitals for quality measurement and metrics reporting. The data will be utilized to develop strategic treatment pathways that will improve patient care. Ultimately, the goal of the registry is to enhance the understanding of treatment associated with knee and hip replacement and the resulting patient outcomes. The registry will also be used to provide quality measurement and metrics reporting.
In the present follow-up study no interventions are administered. This group encompasses patients who had been part of the intervention group of the completed RCT DIQOL with the following intervention: Patients answered QoL questionnaires after surgery and at 3, 6, 12, and 18 months postoperatively. Results were transferred to a QoL-profile consisting of 13 QoL scales. Three experts with various professional background used the individual patient's QoL-profile and clinical and sociodemographic information to generate a QoL-report including therapy recommendations which was sent to the patient's doctor. Specific therapeutic options for the treatment of QoL had been defined: pain therapy, psychotherapy, social support, nutrition counseling, stoma care, physiotherapy, and fitness.
The invention discloses an extraction method and purifying technology of propolis flavones. freezing the propolis medicinal material and crushing, adding water, ethanol, ethyl acetate, cold leaching overnight and leaching, the filter residue is added with ethanol and ethyl acetate for microwave extraction, depressurizing and recovering the solvent, the condensate is extracted by using ethyl acetate, washing the liquid extract and drying by using anhydrous sodium sulphate to obtain concentrated solution of propolis flavones. Using adsorption chromatography method -gradient wash out technology to purify total flavonoids of propolis. The collected eluant is proceeded with rotary evaporation and condensation to form a supersaturated solution to precipitate crystal, and crystal is obtained. Thecrystal is analyzed by high efficiency liquid chromatography (HPLC), the crystals containing similar component and high content of flavones are merged to obtain the prepared total flavonoids of propolis. The invention has simple process, and uses mixed solvent method combined with microwave method can refine active ingredient of the propolis flavones, then uses chromatography purifying process toobtain propolis flavones product with higher purity. The extract will has good application prospect in development of antineoplastic drugs.
The present invention relates to a therapeutic method which enables reprogramming immune system that causes autoimmunity in T1D (Type 1 Diabetes) and also the production of glucose responsive insulin secreting tissues by means of developing new' techniques in endocrine pancreatic engineering. In the invention, in the new' generation insuring synthesizing tissue production method, by means of using decellularization and 3D printing techniques in combination, which are two different fields of tissue engineering, a hybrid printing technique is developed, and thus a bioactive matrix production re-printed by using stem cells of extracellular matrix of the pancreas is carried out. Insulin producing beta cells are obtained by means of differentiation of autologous mesenchymal stem cells and insulin secreting endocrine pancreas-like functional tissue pice production is provided. In the present invention, first the autoimmune immune system, which attacks the insulin-producing β-cel!s in T1D, is suppressed as the therapeutic method for the treatment of T1D. After autoimmune attacks are prevented in individual with T1D, the insulin producing tissue piece created within the scope of the invention is transplanted to individuals with T1D as subcutaneous biochips. Therefore, the said endocrine pancreas-like tissue called as biochip secretes insulin in response to glucose in diabetic individuals, and can bring the blood sugar· to a healthy level.
Human papillomavirus (HPV) is the most common sexually transmitted infection in the US and worldwide, with more than 42 million Americans infected with types of HPV that are known to cause disease. While the link between HPV and the development of a variety of cancers has been strongly established, recent literature has demonstrated a potential association between HPV and increased risk of cardiovascular disease. Nevertheless, despite plausible mechanisms for the development of cardiovascular disease with HPV infection, a causative relationship has yet to be firmly established, in part due to potential confounding risk factors between the two. In this 2-part series, we discuss the emerging relationship between HPV and cardiovascular disease. In part 2, we focus on novel risk factors for HPV infection and cardiovascular disease including adverse childhood events, socioeconomic status, and immunosuppression. We conclude with potential prevention and treatment strategies for HPV-related cardiovascular disease, as well as the future direction of the research.
1,129,527. Setting hair. L'OREAL. 15 Nov., 1965 [19 Nov., 1964: 16 Feb., 1965], No. 48449/65. Heading DIP. Hair is permanently set by subjecting it while constrained on rollers having a diameter of at least 15 mm to the action of an aqueous composition containing in admixture at least one thiol and at least one .disulphide of a thiol the molar concentration of the disulphide being at least equal to that of the thiol, drying the hair and then removing it from the rollers. The thiol may be thioglycolic acid, thiolactic acid, glycol thioglycolate, glycerol thioglycolate, glycol thiolactate, #-mercaptoethanol, N- carboxymethyl-mercapto-acetamide or thioglycerol and suitable disulphides are those of .these thiols. The disulphide may be produced in situ by oxidation of the thiol with hydrogen peroxide, sodium iodate, sodium periodate or sodium bromate. The composition preferably contains 0.1-10% by weight of the thiol and has pH of 8.5-9.5. It may also contain synthetic resins, e.g. polyvinyl pyrrolidone, or a vinyl pyrrolidone/vinyl acetate copolymer, or polysulphydrylated polymer obtained by the reaction of #-mercaptoethyl-amine with an ethylene/maleic anhydride copolymer, ammonia, urea and ethyl alcohol. The composition may be applied to the hair before or after it is wound up on rollers and allowed to act on the hair for .not more than 30 minutes, the hair then being rinsed, dried and removed from the rollers..Hair may be waved or-straightened by the process.
Semaphorin3E (Sema3E) is a member of axon guidance proteins that have emerged recently as essential regulators of cell migration and proliferation. It binds to PlexinD1 with high affinity and is expressed in different cell types, including immune, cancer, and epithelial cells. Recent work in our lab has revealed a critical immunoregulatory role of Sema3E in experimental allergic asthma; however, its role in chronic obstructive pulmonary disease (COPD) remains unclear. This study aimed to investigate the expression of Sema3E and its receptor, PlexinD1, in the airways of patients with COPD and whether Sema3E regulates airway smooth muscle (ASM) cell proliferation, a key feature of airway remodeling in COPD. We first demonstrate that human ASM cells obtained from COPD express Sema3E and PlexinD1 at both mRNA and protein levels. Also, bronchial sections from patients with COPD displayed immunoreactivity of Sema3E and its receptor PlexinD1, suggestive of functional contribution of Sema3E in airway remodeling. In contrast to ASM cells from healthy donors, Sema3E did not inhibit the platelet-derived growth factor (PDGF) induced cell proliferation in ASM cells of patients with COPD that were consistent with the binding of endogenous Sema3E to its receptors on the cell surface and the expression and release of p61KDa-Sema3E isoform. Our results support the Sema3E-PlexinD1 axis involvement in COPD airway smooth muscle remodeling.NEW & NOTEWORTHY Semaphorin3E (Sema3E), a protein guiding cell movement, is found in various cell types like neural, immune, cancer, and epithelial cells. This study examines Sema3E in chronic obstructive pulmonary disease (COPD) airways. In patients with COPD, airway smooth muscle cells express Sema3E and its receptor PlxD1. Unlike healthy cells, Sema3E does not hinder cell proliferation in COPD, indicating involvement in airway remodeling. These findings highlight the Sema3E-PlxD1 axis in COPD airway changes.
Patients will receive placebo to LLG783 i.v. infusion every 4 weeks for 12 weeks.
Disclosed are biocompatible polymeric nanoparticles for drug delivery and a method for preparing the same. They can be prepared by mixing a tri-block copolymer, PEG, and a drug at a predetermined temperature to give a homogeneous polymeric mixture; solidifying the homogeneous polymeric mixture at room temperature; and dissolving the solidified polymeric mixture in an aqueous solution. Based on a polymer melting process, the method makes it easy to produce poloxamer nanoparticles at low cost. The nanoparticles show desired particle sizes suitable for use in drug delivery and a uniform particle size distribution. Consisting of a bilayer structure, the nanoparticles can contain sparingly soluble drugs. Also, the nanoparticles contain no organic solvents and are thus safe to the body because they are free of organic solvent residuals. Further, after being administered into the body, the nanoparticles with a high content of sparingly soluble drug entrapped therein can safely deliver the drug to target sites and stably release the drug at a controlled rate.
Female subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.